top of page



Dr Stephen Burbidge has over 20 years experience within the pharmaceutical industry, working in both biotech and large multi-national pharma organisations. From 2009 to 2018, he held positions of increasing responsibility at Proximagen Ltd, Cambridge, UK and from 2014-2018 held the role of Head of Discovery and Preclinical Projects. During this period, he led multiple Discovery and preclinical stage programmes leading to the selection of multiple clinical candidates, of which 3 molecules were progressed into clinical studies. Of note is a VAP-1 inhibitor which is now in Phase 2 clinical development and licensed to Roche. Dr Burbidge supported preclinical activities at Proximagen, including executing multiple non-GLP and GLP toxicology studies. Dr Burbidge also supported due diligence activities for both in-licensing and out-licensing opportunities.
From 1996 to 2008, Dr Burbidge held roles of increasing responsibility at GlaxoWellcome and GlaxoSmithKline. From 2006 to 2008, Dr Burbidge was seconded to the Centre of Excellence for External Drug Discovery where he led drug discovery programmes in collaboration with 4 partner companies (biotech, Europe and US based). From 1996 to 2006, Dr Burbidge was involved in early-stage drug discovery with a focus on Neuroscience. During this period, he supported both small and large molecule programmes as well as having a particular interest in ion channel drug discovery. Dr Burbidge has authored a number of publications in peer-reviewed journals. Dr Burbidge received his BSc and PhD from the University of Warwick (UK).

Steve Mk2 Cropped.png
bottom of page